Xiujuan Gui
Overview
Explore the profile of Xiujuan Gui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin Q, Li S, Shang T, Gui X, Zhu L, Yang Y, et al.
BMJ Open
. 2025 Feb;
15(1):e089188.
PMID: 39894515
Objective: Our study aims to evaluate the spatial and temporal changes of breast-conserving surgery (BCS) rates and influential factors of BCS in Guangdong Province, China. Design, Setting And Participants: This...
2.
Zhao J, Yu Y, Ren W, Ding L, Chen Y, Yuan P, et al.
MedComm (2020)
. 2024 Dec;
6(1):e70031.
PMID: 39712455
This multicenter, single-arm, phase II clinical trial (NCT04034589) evaluated the efficacy and safety of pyrotinib combined with fulvestrant in patients with HR-positive/HER2-positive metastatic breast cancer who had experienced trastuzumab treatment...
3.
Chen X, Huang H, Huang H, Yong J, Zhu L, Chen Q, et al.
Nat Commun
. 2024 Oct;
15(1):9144.
PMID: 39443446
Oral corticosteroids represents the most prevalent treatment for idiopathic granulomatous mastitis. Ductal lavage with triamcinolone acetonide and antibiotics followed by observation (DL-OBS) has emerged as a novel strategy, but a...
4.
Chen H, Gui X, Zhou Z, Su F, Gong C, Li S, et al.
Breast
. 2024 Apr;
75:103733.
PMID: 38615482
Introduction: The impact of distinct estrogen receptor (ER) and progesterone receptor (PR) expression patterns on tumor behavior and treatment outcomes within HER2-positive breast cancer is not fully explored. This study...
5.
Gui X, Zhao J, Ding L, Chai J, Lai H, Cai Y, et al.
Front Oncol
. 2023 Oct;
13:1276976.
PMID: 37869095
Aim: The aim of this study was to identify potential safety concerns associated with Sacituzumab Govitecan (SG), an antibody-drug conjugate targeting trophoblastic cell-surface antigen-2, by analyzing real-world safety data from...
6.
Zhao J, Yang Y, Pang D, Yu Y, Lin X, Chen K, et al.
Ann Transl Med
. 2020 Dec;
8(21):1446.
PMID: 33313191
Background: The overall survival (OS) among patients with advanced breast cancer (ABC) varies greatly. Although molecular subtype is known as the most important factor in OS differentiation, significant differences in...
7.
Ou L, Lin H, Song Y, Tan G, Gui X, Li J, et al.
Int J Nanomedicine
. 2020 Aug;
15:5131-5146.
PMID: 32764941
Background: Gene therapy is considered a novel way to treat osteosarcoma, and microRNAs are potential therapeutic targets for osteosarcoma. miR-214 has been found to promote osteosarcoma aggression and metastasis. Graphene...
8.
Liu N, Zhu M, Linhai Y, Song Y, Gui X, Tan G, et al.
Oncol Rep
. 2018 Sep;
40(5):2997-3005.
PMID: 30226606
Upregulated β-galactoside α2,6-sialyltransferase I (ST6Gal-I) expression reportedly occurs in many cancers and is correlated with metastasis and poor prognosis. However, the mechanisms by which ST6Gal‑I facilitates gastric cancer progression remain...
9.
Tan G, Chu C, Gui X, Li J, Chen Q
Medicine (Baltimore)
. 2018 Mar;
97(13):e0197.
PMID: 29595655
Background: Circulating cell-free DNA (cfDNA) isolated from plasma or serum by noninvasive procedures can serve as a "liquid biopsy" and has potential as a biomarker for the tumor burden and...
10.
Gui X, Zhu X, Guo L, Tan G, Liu Y, Tan Y, et al.
Medicine (Baltimore)
. 2017 Dec;
96(49):e8877.
PMID: 29245252
Rationale: Thymomas are associated with numerous autoimmune disorders, such as myasthenia gravis (MG), pure red cell aplasia (PRCA), and systemic lupus erythematosus (SLE). However, graft-versus-host disease (GVHD)-like erythroderma is a...